Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time Reporting.

Autor:	Tulling AJ; From the Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands., Lugthart G; From the Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands., Mooij MG; Department of Pediatric Nephrology, Sophia Children's Hospital, Erasmus MC, Rotterdam, the Netherlands., Brackel CLH; Department of Pediatrics, Tergooi MC, Hilversum, the Netherlands., Terheggen-Lagro SWJ; Department of Pediatric Pulmonology, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, the Netherlands., Oostenbrink R; Department of General Pediatrics, Sophia Children's Hospital, Erasmus MC, Rotterdam, the Netherlands., Buysse CMP; Department of Pediatric Intensive Care, Sophia Children's Hospital, Erasmus MC, Rotterdam, the Netherlands., Hashimoto S; Department of Pediatric Pulmonology, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, the Netherlands., Armbrust W; Department of Pediatric Rheumatology, University Medical Center Groningen, Groningen, the Netherlands., Bannier MAGE; Department of Pediatrics, University Medical Center Maastricht, Maastricht, the Netherlands., Bekhof J; Department of Pediatrics, Isala Hospital, Zwolle, the Netherlands., van Gameren-Oosterom HB; Department of Pediatrics, Groene Hart Hospital, Gouda, the Netherlands., Hendriks H; Department of Pediatrics, Zuyderland Medical Center, Heerlen, the Netherlands., van Houten MA; Department of Pediatrics, Spaarne Gasthuis, Hoofddorp, the Netherlands., van der Linden JW; Department of Pediatrics, Bernhoven, Uden, the Netherlands., Lebon A; Department of Pediatrics, Albert Schweitzer Hospital, Dordrecht, the Netherlands., van Onzenoort-Bokken L; Department of Pediatrics, Máxima Medical Center, Veldhoven, the Netherlands., Tramper-Stranders GA; Department of Pediatrics, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands., van Veen M; Department of Pediatrics, Juliana Children's Hospital, Hagaziekenhuis, the Hague, the Netherlands., von Asmuth EGJ; From the Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands., Buddingh EP; From the Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.
Jazyk:	angličtina
Zdroj:	The Pediatric infectious disease journal [Pediatr Infect Dis J] 2023 Dec 01; Vol. 42 (12), pp. 1077-1085. Date of Electronic Publication: 2023 Oct 12.
DOI:	10.1097/INF.0000000000004098
Abstrakt:	Background: SARS-CoV-2 variant evolution and increasing immunity altered the impact of pediatric SARS-CoV-2 infection. Public health decision-making relies on accurate and timely reporting of clinical data. Methods: This international hospital-based multicenter, prospective cohort study with real-time reporting was active from March 2020 to December 2022. We evaluated longitudinal incident rates and risk factors for disease severity. Results: We included 564 hospitalized children with acute COVID-19 (n = 375) or multisystem inflammatory syndrome in children (n = 189) from the Netherlands, Curaçao and Surinam. In COVID-19, 134/375 patients (36%) needed supplemental oxygen therapy and 35 (9.3%) required intensive care treatment. Age above 12 years and preexisting pulmonary conditions were predictors for severe COVID-19. During omicron, hospitalized children had milder disease. During population immunity, the incidence rate of pediatric COVID-19 infection declined for older children but was stable for children below 1 year. The incidence rate of multisystem inflammatory syndrome in children was highest during the delta wave and has decreased rapidly since omicron emerged. Real-time reporting of our data impacted national pediatric SARS-CoV-2 vaccination- and booster-policies. Conclusions: Our data supports the notion that similar to adults, prior immunity protects against severe sequelae of SARS-CoV-2 infections in children. Real-time reporting of accurate and high-quality data is feasible and impacts clinical and public health decision-making. The reporting framework of our consortium is readily accessible for future SARS-CoV-2 waves and other emerging infections. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu